569253-U

Discovery^® HS C18 (3 µm) HPLC Columns

L × I.D. 5 cm × 2.1 mm, HPLC Column

• Synonym(s): Discovery RP18 HPLC Column
• UNSPSC Code: 41115700
• eCl@ss: 32110501
• NACRES: SB.52

Properties

• product name: Discovery^® HS C18 HPLC Column, 3 μm particle size, L × I.D. 5 cm × 2.1 mm
• material: stainless steel column
• Quality Level: 100
• Agency: suitable for USP L1
• product line: Discovery^®
• feature: endcapped
• manufacturer/tradename: Discovery^®
• packaging: 1 ea of
• extent of labeling: 20% Carbon loading
• parameter: ≤70 °C temp. range; 400 bar pressure (5801 psi)
• technique(s): HPLC: suitable; LC/MS: suitable
• L × I.D.: 5 cm × 2.1 mm
• surface area: 300 m²/g
• surface coverage: 3.2 μmol/m²
• impurities: <10 ppm metals
• matrix: silica gel, high purity, spherical particle platform; fully porous particle
• matrix active group: C18 (octadecyl) phase
• particle size: 3 μm
• pore size: 120 Å
• operating pH range: 2-8
• application(s): food and beverages
• separation technique: reversed phase

Description

General description

Discovery^® HS C18 HPLC column (L × I.D. 5 cm × 2.1 mm) is commonly found to be stable under acidic and basic conditions.

Application

• Stereoselective separation of omeprazole and 5-hydroxy-omeprazole using dried plasma spots and a heart-cutting 2D-LC approach for accurate CYP2C19 phenotyping: This research utilizes the Discovery^® HS C18 HPLC column for its superior selectivity and sensitivity in pharmacogenetic studies, providing vital data for personalized medicine approaches in drug metabolism (Abouir et al., 2024).


• A stability indicating RP-HPLC method for determination of the COVID-19 drug molnupiravir applied using nanoformulations in permeability studies: This study highlights the effectiveness of the Discovery^® HS C18 column in the rapid and accurate analysis of molnupiravir, emphasizing its role in supporting fast-paced pharmaceutical research and development (Reçber et al., 2022).


• Sensitive Analysis of Idarubicin in Human Urine and Plasma by Liquid Chromatography with Fluorescence Detection: This application underlines the Discovery^® HS C18 column′s high sensitivity and robustness in clinical diagnostics, crucial for monitoring therapeutic drugs and their metabolites in complex biological matrices (Maliszewska et al., 2020).

Features and Benefits

• Stable, low bleed for LC-MS applications
• Scalable from analytical to preparatory
• Highly stable to ensure excellent run-to-run and lot-to-lot reproducibility
• Higher hydrophobicity for better resolution of difficult analytes

   

Recommended products

Discover LiChropur reagents ideal for HPLC or LC-MS analysis

Legal Information

Discovery is a registered trademark of Merck KGaA, Darmstadt, Germany